Disease · MONDO_0007009
ureterolithiasis
6 sourcesdiseases-2026-09-18-0.1.0
Download JSON
Cite this record
ConductScience Library. ureterolithiasis. Diseases, record MONDO_0007009. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0007009
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
- Ureteric calculus, Ureteric stone (disorder), Ureterolithiasis (disorder), calculus of ureter, ureteric stone
- Open Targets
Drugs11
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| TAMSULOSIN | CHEMBL836 | Small molecule | Phase 3 | ClinicalTrials.gov | 9 | 9 | 9 | Drugs and targets |
| ALFUZOSIN | CHEMBL709 | Small molecule | Phase 3 | ClinicalTrials.gov | 5 | 5 | 5 | Drugs and targets |
| SILODOSIN | CHEMBL24778 | Small molecule | Phase 3 | ClinicalTrials.gov | 5 | 5 | 5 | Drugs and targets |
| DOXAZOSIN | CHEMBL707 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| NAFTOPIDIL | CHEMBL142635 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| NIFEDIPINE | CHEMBL193 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| PRAZOSIN | CHEMBL2 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| MIRABEGRON | CHEMBL2095212 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| FEXOFENADINE | CHEMBL914 | Small molecule | Unknown | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| PHENIRAMINE MALEATE | CHEMBL1653 | Small molecule | Unknown | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
1 to 10 of 11
See all 11 drugsTargets10
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| ADRA1A | Adrenergic receptor alpha-1 | 5 | Adrenergic receptor alpha-1 agonist; Adrenergic receptor alpha-1 antagonist; Alpha-1a adrenergic receptor antagonist | Phase 3 | https://conductscience.org/library/genes/148 | Drugs and targets |
| ADRA1D | Adrenergic receptor alpha-1 | 5 | Adrenergic receptor alpha-1 agonist; Adrenergic receptor alpha-1 antagonist; Alpha-1d adrenergic receptor antagonist | Phase 3 | https://conductscience.org/library/genes/146 | Drugs and targets |
| ADRA1B | Adrenergic receptor alpha-1 | 4 | Adrenergic receptor alpha-1 agonist; Adrenergic receptor alpha-1 antagonist | Phase 3 | https://conductscience.org/library/genes/147 | Drugs and targets |
| HRH1 | Histamine H1 receptor | 2 | Histamine H1 receptor antagonist | Unknown | https://conductscience.org/library/genes/3269 | Drugs and targets |
| ADRB3 | Beta-3 adrenergic receptor | 1 | Beta-3 adrenergic receptor agonist | Phase 2 | https://conductscience.org/library/genes/155 | Drugs and targets |
| CACNA1C | Voltage-gated L-type calcium channel | 1 | Voltage-gated L-type calcium channel blocker | Phase 3 | https://conductscience.org/library/genes/775 | Drugs and targets |
| CACNA1D | Voltage-gated L-type calcium channel | 1 | Voltage-gated L-type calcium channel blocker | Phase 3 | https://conductscience.org/library/genes/776 | Drugs and targets |
| CACNA1F | Voltage-gated L-type calcium channel | 1 | Voltage-gated L-type calcium channel blocker | Phase 3 | https://conductscience.org/library/genes/778 | Drugs and targets |
| CACNA1S | Voltage-gated L-type calcium channel | 1 | Voltage-gated L-type calcium channel blocker | Phase 3 | https://conductscience.org/library/genes/779 | Drugs and targets |
| PDE5A | cGMP-specific 3',5'-cyclic phosphodiesterase | 1 | Phosphodiesterase 5A inhibitor | Unknown | https://conductscience.org/library/genes/8654 | Drugs and targets |
Trials19
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01144949 | Study of Silodosin to Facilitate Passage of Urinary Stones | Phase 2 | 239 | 2014-08-11 | Ureteral Calculi, Kidney Stones, Urolithiasis | SILODOSIN | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT00448123 | The Efficacy of Tamsulosin in the Treatment of Ureteral Stones in Emergency Department Patients | Not applicable | 127 | 2016-10-12 | Kidney Stones, Ureteral Stones | TAMSULOSIN | Open Targets' reading, confirmed by NLM's indexing of its papers | ClinicalTrials.gov |
| NCT00831701 | Medical Expulsive Therapy of Single Distal Ureteral Stones | Not applicable | 100 | 2010-05-12 | Ureteral Calculi | TAMSULOSIN | Open Targets' reading, confirmed by NLM's indexing of its papers | ClinicalTrials.gov |
| NCT00762424 | Effect of Tamsulosin on Stone Expulsion and Pain Resolution in ED Patients With Ureterolithiasis | Not applicable | 53 | 2014-12-17 | Kidney Stone | TAMSULOSIN | Its record names the disease | ClinicalTrials.gov |
| NCT02744430 | Mirabegron as Medical Expulsive Therapy (MET) for Ureteral Stones and Ureteral Stent Pain | Phase 2 | 33 | 2022-04-26 | Ureteral Obstruction, Flank Pain | MIRABEGRON | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT00713739 | Alfuzosin for Medical Expulsion Therapy of Ureteral Stones | Phase 3 | 240 | Kidney Stones | ALFUZOSIN, DOXAZOSIN, NIFEDIPINE, PRAZOSIN | Open Targets' reading of its record | ClinicalTrials.gov | |
| NCT00454402 | ALF-STONE: Alfuzosin in Uretheric Stones | Phase 3 | 220 | Prostatic Hyperplasia | ALFUZOSIN | Open Targets' reading of its record | ClinicalTrials.gov | |
| NCT06999135 | Comparison of Silodosin and Tamsulosin for Medical Expulsive Therapy in Patients With Ureteral Stones | Not applicable | 200 | Tamsulosin, Silodosin, Medical Expulsive Therapy | SILODOSIN, TAMSULOSIN | Open Targets' reading, confirmed by NLM's indexing of its papers | ClinicalTrials.gov | |
| NCT05789732 | Silodosin, Tadalafil Alone vs. Silodosin Plus Tadalafil as MET for Lower Ureteric Stones | Not applicable | 168 | Lower Ureteric Stones, Medical Expulsive Therapy, Tadalafil, Silodosin | SILODOSIN, TADALAFIL | Open Targets' reading of its record | ClinicalTrials.gov | |
| NCT00409227 | Does Treatment With Alfuzosin Increase Success Rates of (SWL) Shock Wave Lithotripsy | Phase 2 | 150 | Urolithiasis, Nephrolithiasis, Ureterolithiasis | ALFUZOSIN | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 19
See all 19 trialsComparisons in its trials12
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Silodsosin vs Placebo: serious adverse events | 2 of 119 | 2 of 120 | 239 | NCT01144949 | Trial comparisons |
| Silodsosin vs Placebo: Spontaneous Stone Passage (All Stones) Without Need for Emergency Department Visits, Hospital Admissions, Surgical Intervention, or Other Interventional Procedures. | 60 of 115 | 52 of 117 | 232 | NCT01144949 | Trial comparisons |
| Silodsosin vs Placebo: Spontaneous Stone Passage (Distal Stones) Without Need for Emergency Department Visits, Hospital Admissions, Surgical Intervention, or Other Interventional Procedures. | 36 of 52 | 27 of 59 | 111 | NCT01144949 | Trial comparisons |
| Tamsulosin vs Placebo: Stone Passage | 21 of 53 | 18 of 47 | 100 | NCT00448123 | Trial comparisons |
| Tamsulosin vs Placebo: serious adverse events | 0 of 53 | 0 of 47 | 100 | NCT00448123 | Trial comparisons |
| Tamsulosin Treatment vs Placebo Treatment: Number of Participants With Stone Expulsion | 39 of 45 | 40 of 45 | 90 | NCT00831701 | Trial comparisons |
| Tamsulosin Treatment vs Placebo Treatment: Number of Participants Requiring Active Treatment | 6 of 45 | 4 of 45 | 90 | NCT00831701 | Trial comparisons |
| Tamsulosin Treatment vs Placebo Treatment: serious adverse events | 0 of 45 | 0 of 45 | 90 | NCT00831701 | Trial comparisons |
| Tamsulosin vs Placebo: serious adverse events | 0 of 28 | 0 of 25 | 53 | NCT00762424 | Trial comparisons |
| Arm 1 - Active vs Arm 2 - Placebo: Spontaneous Stone Passage Using Fisher's Exact Test | 8 of 17 | 5 of 16 | 33 | NCT02744430 | Trial comparisons |
1 to 10 of 12
See all 12 comparisons in its trialsPapers from its trials14
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0007009
GET https://conductscience.org/api/diseases/v1/MONDO_0007009/drugs